14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
CGEM vs ENTA: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
CGEM Overall Winner
6-Pillar Tally: CGEM 3 – 2 ENTA (1 Tie)
Matrix Metrics: CGEM 8 – 2 ENTA
As of Nov 16, 2026, Cullinan Therapeutics, Inc. (CGEM) is the stronger overall head-to-head candidate over Enanta Pharmaceuticals, Inc (ENTA) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CGEM carries a Unified Composite Score of 41.0/100 (SELL) at $9.50 (6.7x Forward P/E, 0.0% operating margin), whereas ENTA carries 46.2/100 (HOLD) at $10.67 (44.0x Forward P/E, -90.0% operating margin).
Composite vs. Pillar Nuance: While ENTA currently prints a higher short-term Unified Composite Score (46.2/100 HOLD vs. CGEM 41.0/100 SELL), CGEM captures the overall institutional head-to-head verdict (8–2 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -90.0% operating margin) and revenue trajectory (+0.0% vs. -21.6% YoY).
Technical & Structure Timing Caution: CGEM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.9); meanwhile ENTA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 43.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CGEM vs ENTA. Trailing 12-month operating profitability (CGEM 0.0% vs ENTA -90.0%) and valuation multiples (CGEM 6.7x vs ENTA 44.0x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $653.8M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
ENTA Moat ProfileCyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $326.2M market capitalization and -90.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ CGEM vs ENTA Key Questions & Quantitative Answers
As of Nov 16, 2026, Cullinan Therapeutics, Inc. (CGEM) is the stronger overall head-to-head candidate over Enanta Pharmaceuticals, Inc (ENTA) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CGEM carries a Unified Composite Score of 41.0/100 (SELL) at $9.50 (6.7x Forward P/E, 0.0% operating margin), whereas ENTA carries 46.2/100 (HOLD) at $10.67 (44.0x Forward P/E, -90.0% operating margin). Composite vs. Pillar Nuance: While ENTA currently prints a higher short-term Unified Composite Score (46.2/100 HOLD vs. CGEM 41.0/100 SELL), CGEM captures the overall institutional head-to-head verdict (8–2 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -90.0% operating margin) and revenue trajectory (+0.0% vs. -21.6% YoY). Technical & Structure Timing Caution: CGEM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.9); meanwhile ENTA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 43.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CGEM leads the Growth & Scale pillar: CGEM posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with ENTA at -21.6% YoY revenue growth and -66.2% YoY earnings growth on $65M TTM revenue (100.0% gross margin, -90.0% operating margin). On trailing 12-month operating scale, CGEM generates N/A in USD-normalized revenue versus $65M for ENTA. In operating R&D and SG&A reinvestment, CGEM deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ENTA.
CGEM screens cheaper on headline valuation multiples. CGEM trades at 6.7x Forward P/E, 6.7x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas ENTA trades at 44.0x Forward P/E, 44.0x Trailing P/E, N/M PEG, and 5.3x EV/Revenue (-56.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CGEM (-50.3% ROE) versus ENTA (-70.1% ROE) capital efficiency.
In options market volatility and institutional positioning, CGEM carries 124.5% implied volatility (9th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.59β · 105% Vol realized risk). By comparison, ENTA carries 78.7% implied volatility (11th %ile, Compressed (<25th %ile)), a 0.31x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.88β · 58% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.